Insights into the evolution of lymphomas induced by epstein-barr virus

Advances in Cancer Research

Volumn 108, Issue C, 2010, Pages 1-19

  Vereide, David ^a   Sugden, Bill ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

B CELL LYMPHOMA; BOOK; BURKITT LYMPHOMA; CARCINOGENESIS; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL LYMPHOMA; NONHUMAN; PLASMID; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR CELL; VIRUS GENE;

EID: 77958490907     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380888-2.00001-7     Document Type: Chapter

References (74)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Altmann M., Hammerschmidt W. Epstein-Barr virus provides a new paradigm: A requirement for the immediate inhibition of apoptosis. PLoS Biol. 2005, 3:e404.
3. Altmann M., Pich D., Ruiss R., Wang J., Sugden B., Hammerschmidt W. Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc. Natl. Acad. Sci. USA 2006, 103:14188-14193.
4. Anderton E., Yee J., Smith P., Crook T., White R.E., Allday M.J. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: Clues to the pathogenesis of Burkitt's lymphoma. Oncogene 2008, 27:421-433.
5. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 1998, 9:395-404.
6. Babcock G.J., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000, 13:497-506.
7. Blake N., Lee S., Redchenko I., Thomas W., Steven N., Leese A., Steigerwald-Mullen P., Kurilla M.G., Frappier L., Rickinson A. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997, 7:791-802.
8. Boxer R.B., Jang J.W., Sintasath L., Chodosh L.A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6:577-586.
9. Brooks L., Yao Q.Y., Rickinson A.B., Young L.S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 1992, 66:2689-2697.
10. Brousset P., Butet V., Chittal S., Selves J., Delsol G. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab. Invest. 1992, 67:457-464.
11. Cai X., Schafer A., Lu S., Bilello J.P., Desrosiers R.C., Edwards R., Raab-Traub N., Cullen B.R. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2006, 2:e23.
12. Capello D., Cerri M., Muti G., Berra E., Oreste P., Deambrogi C., Rossi D., Dotti G., Conconi A., Vigano M., Magrini U., Ippoliti G., et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 2003, 102:3775-3785.
13. Chaudhuri B., Xu H., Todorov I., Dutta A., Yates J.L. Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus. Proc. Natl. Acad. Sci. USA 2001, 98:10085-10089.
14. Chen F., Zou J.Z., di Renzo L., Winberg G., Hu L.F., Klein E., Klein G., Ernberg I. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 1995, 69:3752-3758.
15. Cheung S.T., Huang D.P., Hui A.B., Lo K.W., Ko C.W., Tsang Y.S., Wong N., Whitney B.M., Lee J.C. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 1999, 83:121-126.
16. Deacon E.M., Pallesen G., Niedobitek G., Crocker J., Brooks L., Rickinson A.B., Young L.S. Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 1993, 177:339-349.
17. Dhar S.K., Yoshida K., Machida Y., Khaira P., Chaudhuri B., Wohlschlegel J.A., Leffak M., Yates J., Dutta A. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 2001, 106:287-296.
18. Di Stasi A., De Angelis B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., Heslop H.E., Brenner M.K., Dotti G., Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
19. Dirmeier U., Neuhierl B., Kilger E., Reisbach G., Sandberg M.L., Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res. 2003, 63:2982-2989.
20. Dirmeier U., Hoffmann R., Kilger E., Schultheiss U., Briseno C., Gires O., Kieser A., Eick D., Sugden B., Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005, 24:1711-1717.
21. Ewald D., Li M., Efrat S., Auer G., Wall R.J., Furth P.A., Hennighausen L. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996, 273:1384-1386.
22. Henle G., Henle W., Diehl V. Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc. Natl. Acad. Sci. USA 1968, 59:94-101.
23. Hislop A.D., Annels N.E., Gudgeon N.H., Leese A.M., Rickinson A.B. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 2002, 195:893-905.
24. Hochberg D., Souza T., Catalina M., Sullivan J.L., Luzuriaga K., Thorley-Lawson D.A. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol. 2004, 78:5194-5204.
25. Hochhaus A., Kreil S., Corbin A.S., La Rosee P., Muller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C., Berger U., Gschaidmeier H., Druker B.J., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
26. Huang D.P., Ho J.H., Henle W., Henle G. Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies. Int. J. Cancer 1974, 14:580-588.
27. Jaffe E.S., Harris N.L., Stein H., Isaacson P.G. Classification of lymphoid neoplasms: The microscope as a tool for disease discovery. Blood 2008, 112:4384-4399.
28. Kaschka-Dierich C., Adams A., Lindahl T., Bornkamm G.W., Bjursell G., Klein G., Giovanella B.C., Singh S. Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature 1976, 260:302-306.
29. Kaye K.M., Izumi K.M., Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 1993, 90:9150-9154.
30. Kelly G.L., Rickinson A.B. Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematol. Am. Soc. Hematol. Educ. Program 2007, 2007:277-284.
31. Kelly G., Bell A., Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 2002, 8:1098-1104.
32. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., Bornkamm G.W., Mautner J., Rickinson A.B., Rowe M. PLoS Pathog. 2009, 5:e1000341.
33. Kelly G.L., Milner A.E., Baldwin G.S., Bell A.I., Rickinson A.B. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 2006, 103:14935-14940.
34. Khanna R., Burrows S.R., Kurilla M.G., Jacob C.A., Misko I.S., Sculley T.B., Kieff E., Moss D.J. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J. Exp. Med. 1992, 176:169-176.
35. Kirchmaier A.L., Sugden B. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J. Virol. 1997, 71:1766-1775.
36. Kis L.L., Nagy N., Klein G., Klein E. Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines. Int. J. Cancer 2003, 104:658-661.
37. Klein E., Kis L.L., Klein G. Epstein-Barr virus infection in humans: From harmless to life endangering virus-lymphocyte interactions. Oncogene 2007, 26:1297-1305.
38. Krysan P.J., Haase S.B., Calos M.P. Isolation of human sequences that replicate autonomously in human cells. Mol. Cell. Biol. 1989, 9:1026-1033.
39. Kuze T., Nakamura N., Hashimoto Y., Sasaki Y., Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: Comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn. J. Cancer Res. 2000, 91:1233-1240.
40. Laichalk L.L., Thorley-Lawson D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 2005, 79:1296-1307.
41. Lam K.M., Syed N., Whittle H., Crawford D.H. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet 1991, 337:876-878.
42. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 1997, 94:12616-12621.
43. Lindahl T., Adams A., Bjursell G., Bornkamm G.W., Kaschka-Dierich C., Jehn U. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J. Mol. Biol. 1976, 102:511-530.
44. Lindner S.E., Sugden B. The plasmid replicon of Epstein-Barr virus: Mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 2007, 58:1-12.
45. Lindstrom M.S., Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin. Cancer Biol. 2002, 12:381-387.
46. Middleton T., Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J. Virol. 1994, 68:4067-4071.
47. Miyashita E.M., Yang B., Babcock G.J., Thorley-Lawson D.A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 1997, 71:4882-4891.
48. Murray R.J., Kurilla M.G., Brooks J.M., Thomas W.A., Rowe M., Kieff E., Rickinson A.B. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 1992, 176:157-168.
49. Nanbo A., Sugden A., Sugden B. The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells. EMBO J. 2007, 26:4252-4262.
50. Niedobitek G., Agathanggelou A., Rowe M., Jones E.L., Jones D.B., Turyaguma P., Oryema J., Wright D.H., Young L.S. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995, 86:659-665.
51. Pallesen G., Hamilton-Dutoit S.J., Rowe M., Young L.S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991, 337:320-322.
52. Park S., Lee J., Ko Y.H., Han A., Jun H.J., Lee S.C., Hwang I.G., Park Y.H., Ahn J.S., et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007, 110:972-978.
53. Polack A., Hortnagel K., Pajic A., Christoph B., Baier B., Falk M., Mautner J., Geltinger C., Bornkamm G.W., Kempkes B. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl. Acad. Sci. USA 1996, 93:10411-10416.
54. Pratt Z.L., Kuzembayeva M., Sengupta S., Sugden B. The microRNAs of Epstein-Barr virus are expressed at dramatically differing levels among cell lines. Virology 2009, 386:387-397.
55. Raab-Traub N., Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47:883-889.
56. Reedman B.M., Klein G., Pope J.H., Walters M.K., Hilgers J., Singh S., Johansson B. Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int. J. Cancer 1974, 13:755-763.
57. Reisman D., Yates J., Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol. Cell. Biol. 1985, 5:1822-1832.
58. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 2004, 11:643-658.
59. Roth J., Daus H., Gause A., Trumper L., Pfreundschuh M. Detection of Epstein-Barr virus DNA in Hodgkin- and Reed-Sternberg-cells by single cell PCR. Leuk. Lymphoma 1994, 13:137-142.
60. Schepers A., Ritzi M., Bousset K., Kremmer E., Yates J.L., Harwood J., Diffley J.F., Hammerschmidt W. Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J. 2001, 20:4588-4602.
61. Sears J., Ujihara M., Wong S., Ott C., Middeldorp J., Aiyar A. The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J. Virol. 2004, 78:11487-11505.
62. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Dahl D.B., Chen M., Cheng Y.J., Westra W.H., Chen C.J., Hildesheim A., Sugden B., Ahlquist P. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006, 66:7999-8006.
63. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Stanhope S.A., Cheng Y.J., Chen C.J., Hildesheim A., Sugden B., Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl. Acad. Sci. USA 2008, 105:5874-5878.
64. Shay J.W., Wright W.E. Hayflick, his limit, and cellular ageing. Nat. Rev. Mol. Cell Biol. 2000, 1:72-76.
65. Shimizu N., Tanabe-Tochikura A., Kuroiwa Y., Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: Malignant phenotypes of BL cells are dependent on EBV. J. Virol. 1994, 68:6069-6073.
66. Siemer D., Kurth J., Lang S., Lehnerdt G., Stanelle J., Kuppers R. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol. Immunol. 2008, 45:3133-3141.
67. Tao Q., Robertson K.D., Manns A., Hildesheim A., Ambinder R.F. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue. Blood 1998, 91:1373-1381.
68. Tierney R.J., Steven N., Young L.S., Rickinson A.B. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 1994, 68:7374-7385.
69. Timms J.M., Bell A., Flavell J.R., Murray P.G., Rickinson A.B., Traverse-Glehen A., Berger F., Delecluse H.J. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: Similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003, 361:217-223.
70. Watanabe A., Maruo S., Ito T., Ito M., Katsumura K.R., Takada K. J. Virol. 2010, 84:2893-2901.
71. Xia T., O'Hara A., Araujo I., Barreto J., Carvalho E., Sapucaia J.B., Ramos J.C., Luz E., Pedroso C., Manrique M., Toomey N.L., Brites C., et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res. 2008, 68:1436-1442.
72. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.
73. Zhu J.Y., Pfuhl T., Motsch N., Barth S., Nicholls J., Grasser F., Meister G. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J. Virol. 2009, 83:3333-3341.
74. Zimber-Strobl U., Kempkes B., Marschall G., Zeidler R., Van Kooten C., Banchereau J., Bornkamm G.W., Hammerschmidt W. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 1996, 15:7070-7078.